Algert Global LLC Has $2.55 Million Stake in Masimo Co. (NASDAQ:MASI)

Algert Global LLC lifted its stake in shares of Masimo Co. (NASDAQ:MASI) by 37.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,139 shares of the medical equipment provider’s stock after acquiring an additional 5,260 shares during the period. Algert Global LLC’s holdings in Masimo were worth $2,552,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. NBC Securities Inc. raised its holdings in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. Fifth Third Bancorp raised its stake in Masimo by 16.4% during the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 98 shares during the period. Oak Thistle LLC raised its stake in Masimo by 5.2% during the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after buying an additional 103 shares during the period. GAMMA Investing LLC boosted its holdings in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares in the last quarter. Finally, HHM Wealth Advisors LLC grew its stake in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. 85.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. BTIG Research upped their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company raised their price objective on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research report on Wednesday, November 6th. Piper Sandler raised their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Trading Down 3.1 %

Shares of MASI stock opened at $172.26 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a market capitalization of $9.22 billion, a price-to-earnings ratio of 118.80 and a beta of 0.97. Masimo Co. has a 52-week low of $91.60 and a 52-week high of $178.27. The company has a 50-day simple moving average of $145.90 and a two-hundred day simple moving average of $128.73.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. Research analysts anticipate that Masimo Co. will post 4.04 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.